Posted by AGORACOM-JC
at 7:58 AM on Monday, November 16th, 2020
Announced today the launch of two therapeutic studies on small and large animals examining the therapeutic efficacy of Innocan’s CBD loaded liposome platform technology (“LPT”) in relevant diseases
These studies follow the results of previous studies which demonstrated the prolonged release of Cannabidiol for at least 3 weeks into the blood of mice and rats after a single injection
The new studies will be conducted by the Hebrew University of Jerusalem
Herzliya, Israel and Calgary, Alberta–(November 16, 2020) – Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (the “Company” or “Innocan“), is pleased to announce today the launch of two therapeutic studies on small and large animals examining the therapeutic efficacy of Innocan’s CBD loaded liposome platform technology (“LPT”) in relevant diseases. These studies follow the results of previous studies which demonstrated the prolonged release of Cannabidiol for at least 3 weeks into the blood of mice and rats after a single injection. The new studies will be conducted by the Hebrew University of Jerusalem.
The original study which was led by Dr. Ahuva Cern, Senior Researcher in the lab of Prof. Barenholz at the Hebrew University in Jerusalem found significant amounts of CBD in mices’ blood and muscles up to 21 days after they were injected intramuscular with a single injection of CBD using LPT. The same findings were also demonstrated in rats.
These results are substantial when compared to oral or smoking administration of CBD, in which CBD was found in the blood only for a period of up to 36 hours after one administration.
The results of this study may indicate that Innocan’s LPT, with an injection only once or twice a month, may relieve pain or other symptoms when using CBD. These results may open the door for future experiments to prove a lack of toxicity and therapeutic efficacy of this formulation.
Innocan Israel, a wholly owned subsidiary of Innocan, has entered into a worldwide exclusive research and license agreement with Yissum Research and Development Company (“Yissum“), the commercial arm of the Hebrew University of Jerusalem in Israel, in respect of the design, preparation, characterization and evaluation of hydrogels containing CBD (or other cannabinoid) loaded liposomes. The development is led by Prof. Chezy Barenholz, head of the Membrane and Liposome department at the Hebrew University, who invented over 55 patent families, two of which underlie Doxil – the first FDA approved nano-drug aim for cancer treatment. This LPT unique technology platform may be effective for several applications (such as epilepsy, pain relief, and different inflammation and central nervous system disorders). A patent was filed by Innocan Israel on the LPT technology on October 7, 2019.
Prof. Chezy Berenholz, head of the Laboratory of Membrane and Liposome Research of the Hebrew University stated: ” I believe that these additional animal and efficacy studies are extremely important and may result in a major milestone. This may open a wide range of clinical applications, while maintaining the CBD level in the blood for a long period of time which may lead to better patient compliance. If successful, the technology may be beneficial for various indications”.
About Innocan
The Company, is a pharmaceutical tech company that focuses on the development of several drug delivery platforms containing CBD. Innocan Israel and Ramot at Tel Aviv University, are collaborating on a new, revolutionary exosome-based technology that targets both central nervous system (CNS) indications and the Covid-19 Corona Virus using CBD. CBD-loaded exosomes hold the potential to help in the recovery of infected lung cells. This product, which is expected to be administrated by inhalation, will be tested against a variety of lung infections.
Innocan Israel signed a worldwide exclusive license agreement with Yissum, the commercial arm of the Hebrew University of Jerusalem, to develop a CBD drug delivery platform based on a unique-controlled release liposome to be administrated by injection. Innocan Israel plans, together with Professor Berenholz Head of the Laboratory of Membrane and Liposome Research of the Hebrew University, to test the liposome platform on several potential indications. Innocan Israel is also working on a dermal product that integrates CBD with other pharmaceutical ingredients as well as the development and sale of CBD-integrated pharmaceuticals, including, but not limited to, topical treatments for the relief of psoriasis symptoms as well as the treatment of muscle pain and rheumatic pain. The founders and officers of Innocan Israel have commercially successful track records in the pharmaceutical and technology sectors in Israel and globally.
For further information, please contact:
For Innocan Pharma Corporation: Iris Bincovich, CEO +972-54-3012842 [email protected]
NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.
Caution regarding forward-looking information
Certain information set forth in this news release, including, without limitation, information regarding the markets, requisite regulatory approvals and the anticipated timing for market entry, is forward-looking information within the meaning of applicable securities laws. By its nature, forward-looking information is subject to numerous risks and uncertainties, some of which are beyond Innocan’s control. The forward-looking information contained in this news release is based on certain key expectations and assumptions made by Innocan, including expectations and assumptions concerning the anticipated benefits of the products, satisfaction of regulatory requirements in various jurisdictions and satisfactory completion of requisite production and distribution arrangements.
Forward-looking information is subject to various risks and uncertainties which could cause actual results and experience to differ materially from the anticipated results or expectations expressed in this news release. The key risks and uncertainties include but are not limited to: general global and local (national) economic, market and business conditions; governmental and regulatory requirements and actions by governmental authorities; and relationships with suppliers, manufacturers, customers, business partners and competitors. There are also risks that are inherent in the nature of product distribution, including import / export matters and the failure to obtain any required regulatory and other approvals (or to do so in a timely manner) and availability in each market of product inputs and finished products. The anticipated timeline for entry to markets may change for a number of reasons, including the inability to secure necessary regulatory requirements, or the need for additional time to conclude and/or satisfy the manufacturing and distribution arrangements. As a result of the foregoing, readers should not place undue reliance on the forward-looking information contained in this news release concerning the timing of launch of product distribution. A comprehensive discussion of other risks that impact Innocan can also be found in Innocan’s public reports and filings which are available under Innocan’s profile at www.sedar.com.
Readers are cautioned that undue reliance should not be placed on forward-looking information as actual results may vary materially from the forward-looking information. Innocan does not undertake to update, correct or revise any forward looking information as a result of any new information, future events or otherwise, except as may be required by applicable law.
Posted by AGORACOM-JC
at 7:29 AM on Monday, November 16th, 2020
Announced it has received approval to officially “uplist” from the Pink® market to the OTCQB Venture Market
The common shares will trade under the symbol FUNFF effective as of the opening of the market on November 16, 2020.
Vancouver, British Columbia–(November 16, 2020) – FansUnite Entertainment Inc (CSE: FANS) (OTCQB: FUNFF) (“FansUnite” or the “Company”), a sports and entertainment company, focusing on its technology related to regulated online sports betting and related products, is pleased to announce it has received approval to officially “uplist” from the Pink® market to the OTCQB Venture Market (“OTCQB”). The common shares will trade under the symbol FUNFF effective as of the opening of the market on November 16, 2020.
“We have seen an increased interest from American investors as the online betting space gains traction worldwide,” said Scott Burton, CEO of FansUnite Entertainment. “By upgrading our ticker, we will have increased visibility and exposure to a broader investment community. As we continue to execute on our vision of becoming a global iGaming leader, we are excited to showcase our achievements to a growing base of U.S. and international investors.”
The OTCQB is a Venture Market for early stage and developing U.S. and international companies. Companies are current in their reporting and undergo an annual verification and management certification process. Investors can find Real-Time quotes and market information for the company on https://www.otcmarkets.com.
The move of FansUnite’s shares from Pink Market to OTCQB will not impact or require additional action from shareholders. The stock continues to trade on OTC but now will be accessible through the middle-tier OTC offering. In addition, there will be no change of trading under the Canadian Securities Exchange symbol FANS.
About FansUnite Entertainment Inc.
FansUnite is a global sports and entertainment company, focusing on technology related to regulated and lawful online gaming and other related products. FansUnite has produced a one of a kind complete iGaming platform, Chameleon Gaming Platform, with a sports and esports focus geared for the next generation of online bettors and casino players. The platform includes products for pre-match betting, in-play betting, daily fantasy, content and a certified RNG to produce casino style chance games. The platform operates multiple B2C brands and B2B software for the online gambling industry. FansUnite also looks to acquire technology platforms and assets with high-growth potential in new or developing markets.
For further information, please contact:
Prit Singh Investor Relations at FansUnite [email protected] (905) 510-7636
NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDERS HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.
FORWARD-LOOKING STATEMENTS: Certain information contained herein may constitute “forward-looking information” under Canadian securities legislation. Generally, forward-looking information can be identified by the use of forward-looking terminology such as “believes,” “belief,” “expects,” “intends,” ”anticipates,” “potential,” “should,” “may,” “will,” “plans,” “continue” or similar expressions to be uncertain and forward-looking. Forward-looking statements may include, without limitation, statements relating to future outlook and anticipated events such as:; increased visibility and exposure resulting from trading on the OTCQB; growth of the Company’s base of US and international investors; the Company’s unique portfolio of assets; and discussion of future plans, projections, objectives, estimates and forecasts and the timing related thereto. Forward-looking statements are based on the Company’s estimates and are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of FansUnite to be materially different from those expressed or implied by such forward-looking statements or forward-looking information. Additional information regarding the risks and uncertainties relating to the Company’s business are contained under the heading “Risk Factors” in the Company’s Non-Offering Prospectus dated March 27, 2020 filed on its issuer profile on SEDAR at www.sedar.com and risks related to global pandemics, including the novel coronavirus (COVID-19) global health pandemic, and the spread of other viruses or pathogens and influence of macroeconomic developments. Accordingly, readers should not place undue reliance on forward-looking statements and forward-looking information. The forward-looking statements in this news release are made as of the date of this release. FansUnite disclaims and does not undertake to update or revise any forward-looking statements or forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws.
Posted by AGORACOM-JC
at 7:00 PM on Sunday, November 15th, 2020
The paradigm shifting, parabolic growth of plant based foods and a plant based life is unstoppable, with the plant-based food market alone expected to reach $74.2 billion by 2027.
Plant Based Essentials …. Like Chocolate (Essential? You Bet)
And …… Plant Based …. PLANTS (It’s A BIG Business!)
More than just talk, VEGA is already in full swing and growing FAST
Already Operating In Canada
US Online Operations Kick Off With $USD 25M MIN of PlantX products YEAR 1
6% Royalty Fee to PlantX on gross USA revenues
US Bricks & Mortar with San Diego flagship store opening in DECEMBER
Agreement already signed with a major construction company to build the flagship + franchises across North America
AND ….. The recent £8 million Acquisition of Bloombox In The UK, generating millions in revenue
If you believe in the paradigm shifting nature of plant based foods and more, be sure to watch and share this great interview with PlantX CEO Julia Frank.
Posted by AGORACOM-JC
at 7:30 AM on Friday, November 13th, 2020
Kai Medical Laboratory, a state-of-the-art diagnostics laboratory in Dallas, was acquired by Empower Clinics on October 6, 2020 to further advance the Company’s COVID-19 national testing programs for enterprise clients, including movie and television studios, businesses and colleges
KAI testing volume of 1,375 units in October represents a sequential increase of 763% over testing volume in September of 180 units.
Moreover, the increase comes from only a partial month of control under Empower given the acquisition of KAI was only completed on October 6, 2020.
Finally, given the very recent closing of the acquisition, the record October results were achieved without the benefit of Empower’s planned sales, marketing and rollout plans for KAI.
VANCOUVER, BC / November 13, 2020 / EMPOWER CLINICS INC. (CSE:CBDT)(Frankfurt:8EC)(OTCQB:EPWCF) (“Empower” or the “Company“) an integrated healthcare company serving a database of 165,000 patients through clinics in the southwest United States, a telemedicine platform and medical diagnostics laboratory, is pleased to announce that Kai Medical Laboratory (“KAI”) has achieved record testing volume for the month of October with 1,375 units processed.
RECORD ACHIEVED IN PARTIAL FIRST MONTH UNDER EMPOWER CLINICS
KAI testing volume of 1,375 units in October represents a sequential increase of 763% over testing volume in September of 180 units. Moreover, the increase comes from only a partial month of control under Empower given the acquisition of KAI was only completed on October 6, 2020. Finally, given the very recent closing of the acquisition, the record October results were achieved without the benefit of Empower’s planned sales, marketing and rollout plans for KAI.
Empower Clinics Chairman and CEO, Steven McAuley, stated “The magnitude of KAI’s growth and success in October cannot be overstated as an example of what is to come. This is especially true given the fact we have yet to fully implement the sales and marketing strategies planned for KAI as we expand our national testing programs for enterprise level clients across America. Though we are very pleased with the results achieved in October, the testing volume of 1,375 units represents a fraction of the lab’s capacity which is capable of achieving 4,000 COVID-19 RT-PCR tests per day. It is our intention to continue ramping up growth significantly through 2020 and well into 2021.”
GROWTH STRATEGIES & NUMEROUS NEW COMMERCIAL TESTING CONTRACTS
The Company is now working through integration and implementing aggressive growth strategies including servicing new COVID-19 testing contracts for the film & television industry, banks, restaurants, tourism and supporting the Sun Valley Health COVID-19 RT-PCR and rapid antibody testing programs in the state of Arizona.
To this end, on October 7th, Empower announced it had commenced COVID-19 RT-PCR tests for a major studio film & television production. On October 19th, Empower announced a partnership with Loop Insights to provide the first ever “travel bubble” solution for the global travel industry.
Finally, Empower has signed numerous new commercial testing contracts, the details of which will be provided in subsequent press releases.
To further assist with COVID-19 testing, Kai Medical Laboratory has also developed two key programs in Texas and Arizona. The first program is a direct-to-consumer program that leverages the ability of various healthcare providers to order and administer both the RT-PCR test and the Antibody test. This increases the ability of the general population to be tested, in certain circumstances. The second is an Employer COVID-19 Compliance Program (ECCP) for business owners and employer groups to enable them to test and monitor their employees.
The combination of all this commercial activity since the October 6th acquisition provides the Company with the confidence necessary to support the expectation of much further growth in the months to come.
COVID-19 RT-PCR TESTING IS THE GOLD STANDARD THAT ALLOWS EMPOWER TO ROLL OUT NATIONAL PHASE 4 TESTING PROGRAMS
KAI Medical Laboratory operates a high-complexity CLIA and COLA accredited laboratory that provides reliable and accurate testing solutions to hospitals, medical clinics, pharmacies, and employer groups. KAI has taken an active role in COVID-19 testing, battling the pandemic through RT-PCR testing and serology testing with the capacity to process 4,000 RT-PCR test specimens per day. While the RT-PCR test identifies if a patient has an active virus, the serology or antibody test detects if a patient has previously been exposed to the virus. Both of these test results are vital to managing outbreaks and the potential spread of coronavirus.
As a result of this capability, Empower is now able to expand phase four of its COVID-19 testing rollout which was first announced on April 27, 2020 beginning with testing in-clinic testing (Phase 1) and culminating with a nationwide roll-out across the United States (Phase 4). Phase 4 allows Empower to service enterprise level clients, including movie and television studios that require reliable, accurate, fast and mass batch testing capabilities in order to resume production in a safe and compliant manner.
The Company has also granted an aggregate of 1,079,666 stock options (each, an “Option“) to certain key employees of the Company in accordance with the Company’s stock option plan priced at $0.05 CAD and 1,500,000 Options priced at $0.08 CAD to an investor relations service provider.
This press release is available on the Empower Clinics Verified Forum on AGORACOM for shareholder discussion, questions and engagement with management https://agoracom.com/ir/EmpowerClinics
ABOUT EMPOWER
Empower is creating a network of physicians and practitioners who integrate to serve patient needs, in-clinic, through telemedicine, and with decentralized mobile delivery. A simplified, streamlined care model bringing key attributes of the healthcare supply chain together, always focused on patient experience. The Company provides COVID-19 testing services to consumers and businesses as part of a four-phased nationwide testing initiative in the United States. Empower recently acquired Kai Medical Laboratory, LLC as a wholly owned subsidiary with large-scale testing capability.
This news release contains certain “forward-looking statements” or “forward-looking information” (collectively “forward looking statements”) within the meaning of applicable Canadian securities laws. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Forward-looking statements can frequently be identified by words such as “plans”, “continues”, “expects”, “projects”, “intends”, “believes”, “anticipates”, “estimates”, “may”, “will”, “potential”, “proposed” and other similar words, or information that certain events or conditions “may” or “will” occur. Forward-looking statements in this news release include, but are not limited to, statements regarding: the expected benefits to the Company and its shareholders as a result of the acquisition of Kai Medical Laboratory; the transaction terms; the expected number of clinics and patients following the closing; the future potential success of Kai Medical Laboratory, Sun Valley’s franchise model; the anticipated date of closing of the acquisition and the occurrence thereof; and that the Company will be positioned to be a market-leading service provider for complex patient requirements in 2020 and beyond. Such statements are only projections, are based on assumptions known to management at this time, and are subject to risks and uncertainties that may cause actual results, performance or developments to differ materially from those contained in the forward-looking statements, including: that the Kai Medical Laboratory acquisition may not be completed on the terms expected or at all; that the Company’s products may not work as expected; that the Company may not be able to expand COVID-19 testing; that legislative changes may have an adverse effect on the Company’s business and product development; that the Momentum Health acquisition may not be completed on the terms expected or at all; that the Company may not be able to obtain adequate financing to pursue its business plan; general business, economic, competitive, political and social uncertainties; failure to obtain any necessary approvals in connection with the proposed transaction; and other factors beyond the Company’s control. No assurance can be given that any of the events anticipated by the forward-looking statements will occur or, if they do occur, what benefits the Company will obtain from them. Readers are cautioned not to place undue reliance on the forward-looking statements in this release, which are qualified in their entirety by these cautionary statements. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements in this release, whether as a result of new information, future events or otherwise, except as expressly required by applicable laws.
Posted by AGORACOM-JC
at 4:55 PM on Thursday, November 12th, 2020
When the Facebook data privacy scandal broke out, the world woke up to just how badly our individual data was being traded, used and most importantly, the amount of profit being generated by major corporations at our expense.
This led to the enactment of the biggest data privacy laws in history. Specifically, General Data Protection Regulation (GDPR) out of Europe and the California Consumer Privacy Act (CCPA).
Enter KABN. The Company Turns The Problem Of Data Privacy Into A Profit For Individuals, While Providing Big Businesses With New & Compliant Business Models.
More than just lip service, KABN announced joining the Trust Over IP Foundation, which includes over 170 members including IBM, Mastercard, Accenture and many other global leaders who are defining a complete architecture for Internet-scale digital trust. As part of this community, KABN is focused on bridging the gap between traditional fintech services and solutions and new and innovative Verified Credential processes. Does that sound like a mouthful? Yeah, it does. But all you have to really understand for now is that digital ID, privacy and monetization is going to become a reality in the very near future. Government regulations are enforcing it. Consumers are demanding it and KABN is delivering it at such an advanced scale that the Trust Over IP Foundation has provided them with a strategic role as a Steering Member to help drive the following mission:
“I am certain KABN will make a strong contribution to the Trust over IP Foundation.” said John Jordan, executive director, BC Digital Trust Service and executive director of ToIP. “People and businesses are going to continue using the internet to build relationships and complete transactions digitally with all the risks of security breaches and fraud that go along with it today. It’s time for a change. Global leaders are working together at our Foundation to make it possible for people to be known and to build trusted relationships online. I am happy to have KABN be part of this effort.”
KABN was so ahead of this curve they were actually too early to the game … now the game is underway with KABN sitting in a great field position. Watch this interview with President David Lucatch and welcome to the next potential great disruptive industry of the decade.
Posted by AGORACOM-JC
at 12:18 PM on Thursday, November 12th, 2020
The devastation and destruction of Coronavirus COVID-19 is well documented and doesn’t need much repeating here.
What we do know is that COVID-19 has created global demand for highly specialty products required to protect, test, detect and defend as many people as possible.
Moreover, given its persistence and the potential for a 2nd wave around the world, governments and businesses both big and small are now in need of solutions that go beyond locking down economies by helping them stay open, generate revenue, keep people employed … all while keeping them safe.
There are no magic bullets. COVD-19 didn’t exist 12 months ago, so there are no established or incumbent leaders. This has created an opportunity for small but nimble companies with high-tech expertise to adapt their products as solutions in one of the many verticals that require help fighting COVID-19.
Here are 6 small-cap companies (in alphabetical order) that have provided real solutions to helping the fight against COVID-19.
Datametrex AI Limited (DM:TSXV) (D4G:FSE) (DTMXF: OTC )an AI and Machine learning company was well positioned with deep roots in South Korea to make the ultimate pivot to Covid-19 test kit distribution. When the Canadian Government came calling for assistance in importing and distributing COVID-19 test kits, Datametrex stepped up to the task thanks to its security clearances already in place in both countries.
Since then, the company has signed multiple multi-million dollar Covid-19 test kit supply agreements with mining companies, a $20M CAD agreement with the television and film industry and various educational institutions. This is in addition to lucrative AI contracts with various levels of government and enterprise level customers such as LOTTE Group, the fifth-largest conglomerate in Korea with annual revenues of approximately $60B USD.
REVENUE $CAD
Q1 + 62% To $809,000
Q2 + 419% To $1,954,000
TOTAL Q1 AND Q2
REVENUE $2.8M vs $875K = +220%
GROSS PROFIT $1.2 vs $739K = +62%
Given the speed of incoming contracts, the quarterly financials don’t reflect deals done during the third quarter. Here’s just a few;
Datametrex Expands Distribution of Film and Television Coronavirus Testing Across Canada (October 27, 2020)
Expands to Toronto Film Production Company for COVID-19 Testing Solutions (September 30, 2020)
$20M Supply Agreement With Major Worldwide Media & Entertainment Company for COVID-19 (September 24, 2020)
Received Third COVID-19 Order from TV Production Company (September 21, 2020)
Received COVID-19 Test Kits Order for $1.6M From a Canadian Mining Company (September 3, 2020)
·· The company has also experienced robust demand for related services. Datametrex entered into a sales agreement with 7-Eleven Korea for Robotic Process Automation infrastructure (RPA) in order to automate certain business processes.
The global RPA market size is expected to reach $7.2 billion by 2025, rising at a market growth of 32.6% CAGR during the forecast period. RPA is the technology that enables anyone to configure computer software today, or a “robot” to replicate and incorporate the actions of a person working within digital systems to conduct a business process.
For more information, please visit the Datametrex AI hub on AGORACOM.
Empower (CBDT: CSE) (EPWCF:OTCQB) (8EC:Frankfurt) is a vertically integrated, multi-state operator of medical clinics with a database of over 165,000 patients, a database that almost every medical cannabis and CBD company would kill for …. but that’s not all. In an effort to combat COVID-19 the company’s physician staffed clinics have are also generating significant revenue and growth as follows:
Increased CBD treatments from patients suffering increased anxiety;
Covid-19 Testing for individuals and families
Covid-19 Testing for local businesses and employees
Covid-19 Testing for enterprise level organizations across the country
Empower Clinics and Loop Insights Combine COVID-19 Testing Expertise With Venue Tracing To Create First Ever “Travel Bubble” Solution For Global Travel Industry Set To Lose $3.3 Trillion
How significant is this acquisition that only closed a couple of weeks ago? At the lowest price of $USD 80 per test and operating on just 1,000 tests per day, the clinic would deliver $USD 80,000 in revenue PER DAY.
Patient Visits
Q1 + 377% To 5,717
Q2 + 56% To 6,696
Revenues $USD
Q1 + 416% To $790,000 (NO COVID)
Q2 + 56% To $923.000
TOTAL Q1 AND Q2
REVENUE $1.7M vs $745K = + 130%
PATIENTS 12,400 vs 5,500 = + 125%
NET LOSS $920K vs 1.85M = – 50%
Empower has now delivered growth in 4 successive financial reports (Q4, FY 2019, Q1 and Q2), so it is safe to say that superstar CEO Steve McAuley can officially claim victory on the turnaround he inherited in 2019.
Oh, and did we mention that CEO Steven McAuley is Six Sigma certified under the quality initiative of legendary GE (General Electric) Chairman Jack Welch? We’ve never seen a Six Sigma certified CEO in the Canadian small cap markets. Never. Which explains how McAuley has been able to guide Empower Clinics through the most disruptive retail environment in recent history and turn it into significant growth.
For more information about the company, please check out the Empower HUB on AGORACOM.
Innocan Pharma Corporation (INNO: CSE) (IP4:FSE) is an Israeli based company developing the pharmaceutical guided missile to defeat coronavirus lung infections. The company specializes in the development of new drug platforms which combine unique properties of Cannabinoids.
Innocan, together with Tel Aviv University are developing new, revolutionary exosome based technology (CLX), loaded with cannabidiol (CBD) targeting the coronavirus infected lung cells.
Why is this significant?
CLX may hold the potential to provide anti-inflammatory properties and assist in the recovery of infected lung cells. It is expected to be administrated by inhalation, CLX will be tested on a variety of lung infections focusing on patients infected by the coronavirus disease.
Superior Management Team
More than just lip service, Innocan has a world class management team to make this happen.
In the small cap world, the jockey(s) that drive the horse are just as important as the horse itself. The Innocan Leadership Group Is Incomparable In The Small Cap World, Comprised Of Leading Israeli Pharmaceutical Executives including:
Executive Chairman (Ron Mayron) was the CEO Of Teva Israel, one of the largest generic pharmaceutical companies in the world
Co-Founder & VP Business Development (Yoram Drucker) was the Founder of 2 NASDAQ Companies (Pluristem & Brainstorm)
Chief Technology Officer (Nir Avram) is a former member of the pharma innovation team at Perrigo, producer of OTC consumer goods and specialty pharma.
Chief Executive Officer (Iris Bincovich) has a proven track record in opening global markets, having managed hundreds of successful transactions in OTC, cosmetics and dermatology.
While the Company develops their pharmaceutical solution, Innocan has a portfolio of patent-pending and launch ready consumer health products that are already commercializing around the world as follows:
CONSUMER RETAIL – DERMA COSMETICS – A premium derma cosmetics brand, manufacturing has commenced with distribution agreements in place.
OVER THE COUNTER (OTC) PRODUCTS FOR PAIN RELIEF – patent-pending CBD pain relief brand received FDA technical validation.
Global Manufacturing / Distribution Agreements
To support this global growth, Innocan already has the following relationships in place:
Endless Sky Inc. a Canadian large scale Cannabis extractor (Manufacturing and Distribution – Canada)
Active Therapeutics Ltd of Lancashire, United Kingdom (Distribution – UK and Ireland markets)
For more information about the company, please check out the Innocan Pharma Corporation hub on AGORACOM.
Kontrol Energy is the Google NEST of smart building technology, with a Blue Chip client base to prove it with the likes of Beyond Meat, Toyota, Oxford, Telus and Brookfield to name a few.
As a result, Kontrol is already achieving commercial success as follows:
· Q1 $2.3M
· Q2 $2.7M
TOTAL Q1 AND Q2
REVENUE $5M
GROSS PROFIT $2.7M
ADAPTING CORE TECH TO PROVIDE BLUE CHIP CUSTOMERS WITH REAL-TIME AIR DETECTION OF COVID-19 IN COMMERCIAL BUILDINGS
As a result of the COVID-19 pandemic and the needs of its blue chip customer base, Kontrol is adapting its core technologies team to development and commercialize its Kontrol BioCloud® analyzer, a wall-mounted technology which detects the presence of COVID-19 in the air of commercial buildings and triggers an alert system to provide real time notifications.
GEARING UP PRODUCTION FOR UP TO 20,000 UNITS PER MONTH
Initial expectations, based on lab testing completed to date, is that BioCloud will be effective in small to medium space settings with 3 or more people, and therefore would be suitable for areas such as classrooms, offices, airplanes, trains, buses, long-term care facilities and hospitals. The company is currently building a global supply chain with the goal of being able to supply 20,000 units per month.
The implications of the Kontrol BioCloud® analyzer could be enormous and could have a major impact on the global economy. Paul Ghezzi, CEO of Kontrol Energy has received calls from interested parties spanning the entire globe. In addition, mainstream media has taken notice:
Early tests suggest new Canadian technology could detect the coronavirus in the air Read More
Canadian firm develops tech to ‘detect COVID-19 in the air’; stock doubles Read More.
Kontrol Energy’s BioCloud Featured By Singapore’s IBI Times Read More
CSA APPROVAL RECEIVED ON NOVEMBER 5TH
On Novebmer 5th, KNR announced receipt of CSA standards approval for its BioCloud® technology.
“This is another important milestone for Kontrol and represents the continuing advancement of the BioCloud® technology,” says Paul Ghezzi, CEO Kontrol. “CSA is a Canadian standard for safety and is also accepted in jurisdictions outside Canada. In addition to CSA we continue to work on other important regional certifications including UL and CE for the United States and European markets respectively.”
UL STANDARDS APPROVAL RECEIVED NOVEMBER 12TH
“We continue to execute on the important milestones for commercialization of BioCloud,” says Paul Ghezzi, CEO of Kontrol. “With CSA and UL we now have standards approval that covers Canada, the United States and various other global regions. We continue to work towards CE standards certification which is primarily for the European market.”
DISCLAIMER: The Company has not made any express or implied claims that its product has the ability to eliminate, cure or contain the COVID-19 (or SARS-2 Coronavirus).
For more information about the company, please check out the Kontrol Energy hub on AGORACOM.
Loop Insights (MTRX:TSXV)(RACMF:OTCQB) was already a leading provider of contactless solutions and artificial intelligence (“AI”) to the brick and mortar space prior to the arrival of COVID-19.
Over the last few months Loop has adapted its contactless platform to also provide contact tracing and real-time testing to large venues and businesses. More than just lip service, Loop has already announced significant partnerships and news with the likes of:
“By partnering with innovative and leading IoT development companies, such as Loop, we’re ensuring that our customers have access to some of the most advanced IoT business solutions in the world.”
The presentation ended at approximately 1:15 PM EST, and by 8:00 PM EST Loop had received over 100 direct inquiries from enterprise-level attendees spanning many different industries and countries. Loop Insights anticipates many more direct inquiries to be received in the coming days.
Loop Insights CEO Rob Anson:
“We knew going into the webinar that interest in our Contactless Platform and Solutions was very high given the high-level nature of clients we had already announced leading up to it. These attendees, many of whom represent household name entities, were looking to us for solutions that can protect people, instill confidence in their customers and get their enterprises moving once again. Nonetheless, the response to the demonstration of our Contactless Venue Tracing Platform was simply incredible and even surpassed our expectations. We are optimistic that Loop Insights is establishing an identity as a global force in the contactless space and believe the responses will lead to significant business for Loop. We can’t thank Amazon Web Services enough for their continued support and partnership.”
In addition to these successes, Loop stated that its Venue Tracing platform is clearly gaining recognition and third-party validation, including implementations with:
Implemented Into the Las Vegas flagship properties of a Global Hospitality company (July 23, 2020)
Invited by NCAA DIV 1 BIG EAST CONFERENCE To Present Solution For 11 schools (August 17, 2020)
Partnership with BDG sports to deliver NBA, NHL, NCAA and PGA Sporting Events. (August 13, 2020)
Loop Insights Signs $1,930,000 USD License Deal with Austin, TX Based CasaPerks (September 28, 2020)
Selected as the Premier Venue Tracing and Fan Engagement Solution for NCAA College Basketball “Bubble” in Las Vegas (October 8, 2020)
For more information about the company, please check out the Loop Insights hub on AGORACOM.
Primo Nutraceuticals, a player in the hemp space pivoted early in the pandemic to sell their Primo Lemon Hand Sanitizer in Amazon’s Personal Safety & Household category. The company further solidified its move to PPE by entering into agreement with Duquette Consulting LLC, a company owned by Dan Duquette.
Dan Duquette is a twice named Major League Baseball (MLB) Executive of the Year and former Executive Vice-President of the Baltimore Orioles, General Manager of the Montreal Expos, Boston Red Sox, and Milwaukee Brewers (https://en.wikipedia.org/wiki/Dan_Duquette). Dan Duquette has joined forces with Primo Nutraceuticals to partner in the development, sourcing and the global supply of personal protective equipment products.
The company has been issued a Medical Device Establishment License from Health Canada.The MDEL is a license issued to companies for the activities of manufacturing, importing and distributing of all four classes of medical devices for human use in Canada. These classes include; nitrile gloves, N95 surgical masks & KN95 masks, surgical gowns, respirators and testing kits to name a few.
The PPE Distribution Market worth $28.9 Billion by 2025 in North America and E.U
The North America and Europe distribution market for PPE is expected to reach US$28.95 M by 2025.
The safety-supplies sector in North America is anticipated to witness significant growth of over 7% from 2017 to 2025.
Head, eye and face protection are anticipated to grow at a compound annual growth rate of over 6% from 2017 to 2025.
For more information about the company, please check out the Primo Nutraceuticals hub on AGORACOM.
Thanks for reading and discovering these great small cap companies. Please be sure to visit the AGORACOM Small Cap Coronavirus Covid-19 company gateway often to stay up to date with new companies at:
Posted by AGORACOM-JC
at 9:21 AM on Thursday, November 12th, 2020
There is no denying the world of esports was already on a rapid growth rate prior to the COVID-19 pandemic. However, according to TGS Esports (TGS:TSXV), the growth and awareness of esports over the past several months has accelerated the industry by at least a couple of years, if not more.
Recognizing this trend, TGS pivoted quickly from venue based esports to becoming a leader in esports events, sponsorship and productions. More than just lip service, tournaments hosted to date have been sponsored by the likes of:
Pepsi
Red Bull
7-11
Shaw Cable
More than just events, TGS also creates high quality production value out of these events, which have already seen more than 20,000 hours of viewership on Twitch and featured on GINX Esports TV (Canada), with the potential to expand with GINX to over 50 countries.
If the story ended there, TGS would have the makings of a great early stage esports story …. but it doesn’t
$6 MILLION ACQUISITION OF “PEPPER ESPORTS”
The recent acquisition of Pepper Esports takes the TGS offering to a whole different level by providing everyone from enterprise sized clients to small business to a group of buddies to create their own esports tournaments. The platform is so powerful it will handle everything from registration to game play, prize payouts and everything in between that an entity needs to host a successful esports tournament. Awesome right? No, it gets better.
Hosting your own esports tournament is FREE. TGS and Pepper figured out that the best way to get mass usage of their platform is to make it $0 upfront and generate $$ from revenue share on all transactions that take place during the tournament.
When you bolt on the fact that TGS can now broadcast that tournament, the Company believes its offering can’t be matched anywhere in the world. We like it so much that we’re already considering hosting Agoracom esports tournaments for clients and shareholders who can either play or watch.
Watch this great interview with the CEO’s of both TGS and Pepper to find out more details and feel their mutual excitement about the future.
Posted by AGORACOM-JC
at 9:19 AM on Thursday, November 12th, 2020
Announced a strategic role as a Steering Member of the Trust over IP (“ToIP”) Foundation (www.trustoverip.org).
In taking on this role, KABN joins other Steering Members including Accenture, Anonyme Labs, Continuum Loop, Evernym, Finicity, Futurewei, IBM, ID Ramp, LG CNS, Mastercard and others.
The Trust over IP Foundation has over 170 members, including organizations as well as individuals, collaborating together with the common objective of changing the way people interact online.
TORONTO, ON and GIBRALTAR / November 12, 2020 / The KABN Network together with KABN Systems NA Holdings Corp. (CSE:KABN) (the “Company” or “KABN North America“) (www.kabnsystemsna.com), a Canadian Fintech company that specializes in continuous online identity verification, management and monetization in Canada and the US, today has announced a strategic role as a Steering Member of the Trust over IP (“ToIP”) Foundation (www.trustoverip.org).
In taking on this role, KABN joins other Steering Members including Accenture, Anonyme Labs, Continuum Loop, Evernym, Finicity, Futurewei, IBM, ID Ramp, LG CNS, Mastercard and others. The Trust over IP Foundation has over 170 members, including organizations as well as individuals, collaborating together with the common objective of changing the way people interact online.
The Trust over IP Foundation is defining a complete architecture for Internet-scale digital trust that combines both cryptographic trust at the machine layer and human trust at the business, legal, and social layers. As part of this community, the KABN Network is focused on bridging the gap between traditional fintech services and solutions and new and innovative Verified Credential processes.
KABN aims to use proven bank-grade identity verification processes to allow Holders (who use a credential), Verifiers (who confirm the validity of a credential) and Issuers (who produce the credential) to complete transactions of many kinds including financial services, eCommerce transactions, organization, building and visitor access badges among others.
“I am certain KABN will make a strong contribution to the Trust over IP Foundation.” said John Jordan, executive director, BC Digital Trust Service and executive director of ToIP. “People and businesses are going to continue using the internet to build relationships and complete transactions digitally with all the risks of security breaches and fraud that go along with it today. It’s time for a change. Global leaders are working together at our Foundation to make it possible for people to be known and to build trusted relationships online. I am happy to have KABN be part of this effort.”
Businesses today struggle to protect and manage digital assets and data, especially in an increasingly complex enterprise environment that includes the Internet of Things (IoT), Edge Computing, Artificial Intelligence and much more. This is compounding the already low consumer confidence in the use of personal data and is slowing innovation on opportunities like digital identity and the adoption of new services that can support humanity.
The KABN Network believes that without a global standard for how to ensure digital trust, these struggles are bound to continue. The four layers of Trust over IP’s dual governance and technology stack establish a clear model for how utilities, technical components, business rules and human-focused design can combine to solve this set of problems. The digital trust ecosystems that emerge from Trust over IP will help businesses, citizens and governments alike use the internet to create enduring trusted relationships that allow transactions to be completed safely and with confidence.
“With the ToIP Technology and Governance Stack, the industry is now in a position for an Identity Paradigm shift. Future generations will have a hard time believing that there was a day when everyone was anonymous on the Internet and we believe that the KABN Network is at the forefront of this evolution,” said RJ Reiser, KABN North America CBDO, Director and Co-Chair ToIP Ecosystem Foundry Working Group.
About the Trust over IP Foundation
Launched in 2020, the Trust over IP Foundation is an independent project hosted by the Linux Foundation. Its members include over 150 leading companies, organizations and individual contributors sharing expertise and collaborating to define standard specifications to advance a secure trust layer for the digital world. Through this collaborative effort, the Trust over IP Foundation aims to define a complete architecture for Internet-scale digital trust that combines cryptographic trust at the machine layer with human trust at the business, legal, and social layers. For more information, please visit us at trustoverip.org.
The Linux Foundation has registered trademarks and uses trademarks. For a list of trademarks of The Linux Foundation, please see its trademark usage page: www.linuxfoundation.org/trademark-usage. Linux is a registered trademark of Linus Torvalds.
KABN Systems NA Holdings Corp. through its wholly owned subsidiary KABN Systems North America Inc. focuses on the verification, management and monetization of digital identity, empowering users to control and benefit from its use of their online identity. KABN proprietary technology suite includes 4 key products:
Liquid Avatar allows users to create high quality digital icons representing their online personas. These icons, in conjunction with KABN ID, allow users to manage and control their Digital Identity and to use Liquid Avatars to share public and permission based private data when they want and with whom they want. www.liquidavatar.com
KABN ID is an Always On, biometric and blockchain based digital identity validation and verification platform allowing users to continuously and confidently prove themselves throughout the online community.
KABN Card is a Visa approved prepaid card program allowing users to manage both digital and fiat currencies and earn cashback and other loyalty incentives. www.kabncard.com
KABN KASH is a cashback, loyalty and engagement program that powers the KABN revenue ecosystem.
KABN provides its products and services at no cost to consumers and generates revenues through permission-based partner programs. www.kabnkash.com
David Lucatch Chief Executive Officer 647-725-7742 Ext. 701 [email protected]
The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.
This news release does not constitute an offer to sell, or a solicitation of an offer to buy, any securities under the KABN Financing in the United States. The securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”) or any state securities laws and may not be offered or sold within the United States or to U.S. Persons unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration is available.
Forward-Looking Information and Statements
This press release contains certain “forward-looking information” within the meaning of applicable Canadian securities legislation and may also contain statements that may constitute “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Such forward-looking information and forward-looking statements are not representative of historical facts or information or current condition, but instead represent only the Company’s beliefs regarding future events, plans or objectives, many of which, by their nature, are inherently uncertain and outside of the Company’s control. Generally, such forward-looking information or forward-looking statements can be identified by the use of forward-looking terminology such as “plans”, “expects” or “does not expect”, “is expected”, “budget”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or may contain statements that certain actions, events or results “may”, “could”, “would”, “might” or “will be taken”, “will continue”, “will occur” or “will be achieved”. The forward-looking information and forward-looking statements contained herein may include, but is not limited to, information concerning the ability of the Company to generate revenues, roll out new programs and to successfully achieve business objectives, and expectations for other economic, business, and/or competitive factors.
By identifying such information and statements in this manner, the Company is alerting the reader that such information and statements are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company to be materially different from those expressed or implied by such information and statements. In addition, in connection with the forward-looking information and forward-looking statements contained in this press release, the Company has made certain assumptions. Among the key factors that could cause actual results to differ materially from those projected in the forward-looking information and statements are the following: changes in general economic, business and political conditions, including changes in the financial markets; changes in applicable laws; compliance with extensive government regulation. Should one or more of these risks, uncertainties or other factors materialize, or should assumptions underlying the forward-looking information or statements prove incorrect, actual results may vary materially from those described herein as intended, planned, anticipated, believed, estimated or expected.
Although the Company believes that the assumptions and factors used in preparing, and the expectations contained in, the forward-looking information and statements are reasonable, undue reliance should not be placed on such information and statements, and no assurance or guarantee can be given that such forward-looking information and statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such information and statements. The forward-looking information and forward-looking statements contained in this press release are made as of the date of this press release, and the Company does not undertake to update any forward-looking information and/or forward-looking statements that are contained or referenced herein, except in accordance with applicable securities laws. All subsequent written and oral forward- looking information and statements attributable to the Company or persons acting on its behalf is expressly qualified in its entirety by this notice.
Posted by AGORACOM-JC
at 8:14 AM on Thursday, November 12th, 2020
Kontrol BioCloud a Safe Space Technology™
Received UL standards approval for its BioCloud® technology
As referenced in the press release dated November 5th, 2020, Kontrol has previously received CSA standards approval and has now received UL standards approval.
“We continue to execute on the important milestones for commercialization of BioCloud,” says Paul Ghezzi, CEO of Kontrol. “With CSA and UL we now have standards approval that covers Canada, the United States and various other global regions. We continue to work towards CE standards certification which is primarily for the European market.”
TORONTO, ON / November 12, 2020 / Kontrol Energy Corp. (CSE:KNR)(OTCQB:KNRLF)(FSE:1K8) (“Kontrol” or “Company“) is pleased to announce that it has received UL standards approval for its BioCloud® technology. As referenced in the press release dated November 5th, 2020, Kontrol has previously received CSA standards approval and has now received UL standards approval.
“We continue to execute on the important milestones for commercialization of BioCloud,” says Paul Ghezzi, CEO of Kontrol. “With CSA and UL we now have standards approval that covers Canada, the United States and various other global regions. We continue to work towards CE standards certification which is primarily for the European market.”
Field Certification was provided by ESAFE
Underwriters’ Laboratories or UL regulations require manufacturers of products sold in the United States to receive UL Standards approval for electrical safety.
ESAFE is accredited by the Standards Council of Canada (SCC), as an Inspection Body (ISO 17020) and Certification Body (ISO 17065). As an accredited agency, ESAFE is authorized to approve and label equipment for electrical safety.
BioCloud® is a real-time analyzer designed to detect airborne viruses. It has been designed to operate as a safe space technology by sampling the air quality over time. With a proprietary detection chamber that can be replaced as needed, viruses are detected, and an alert system is created in the Cloud or over local intranet. BioCloud® has been designed for spaces where individuals gather including classrooms, retirement homes, hospitals, mass transportation and others
BioCloud® is not a medical device and the Company is not making any express or implied claims that its product has the ability to eliminate, cure or contain the COVID-19 (or SARS-2 Coronavirus).
About Kontrol Energy
Kontrol Energy Corp. (CSE: KNR) (OTCQB: KNRLF) (FSE: 1K8) is a leader in the energy efficiency sector through IoT, Cloud and SaaS technology. With a disciplined mergers and acquisition strategy, combined with organic growth, Kontrol Energy Corp. provides market-based energy solutions to our customers designed to reduce their overall cost of energy while providing a corresponding reduction in greenhouse gas (GHG) emissions.
For further information, contact:
Paul Ghezzi, Chief Executive Officer [email protected] or [email protected] Kontrol Energy Corp., 180 Jardin Drive, Unit 9, Vaughan, ON L4K 1X8 Tel: 905.766.0400, Toll free: 1.844.566.8123
Neither IIROC nor any stock exchange or other securities regulatory authority accepts responsibility for the adequacy or accuracy of this release.
Forward-Looking Statements
This news release contains “forward-looking information” within the meaning of applicable securities laws. All statements contained herein that are not clearly historical in nature may constitute forward-looking information. In some cases, forward-looking information can be identified by words or phrases such as “may”, “will”, “expect”, “likely”, “should”, “would”, “plan”, “anticipate”, “intend”, “potential”, “proposed”, “estimate”, “believe” or the negative of these terms, or other similar words, expressions and grammatical variations thereof, or statements that certain events or conditions “may” or “will” happen, or by discussions of strategy.
Where the Company expresses or implies an expectation or belief as to future events or results, such expectation or belief is based on assumptions made in good faith and believed to have a reasonable basis. Such assumptions include, without limitation, that sufficient capital will be available to the Company and that technology will be as effective as anticipated.
However, forward-looking statements are subject to risks, uncertainties, and other factors, which could cause actual results to differ materially from future results expressed, projected, or implied by such forward-looking statements. Such risks include, but are not limited to, that sufficient capital and financing cannot be obtained on reasonable terms, or at all, that technologies will not prove as effective as expected, that customers and potential customers will not be as accepting of the Company’s product and service offering as expected, and government and regulatory factors impacting the energy conservation industry. In particular, successful development and commercialization of the Kontrol BioCloud Analyzer (BioCloud®) are subject to the risk that the Kontrol BioCloud Analyzer may not prove to be successful in detecting the virus that causes COVID-19 effectively or at all, uncertainty of timing or availability of any regulatory approvals and Kontrol’s lack of track record in developing products for medical applications.
Accordingly, undue reliance should not be placed on forward-looking statements and the forward-looking statements contained in this press release are expressly qualified in their entirety by this cautionary statement. The forward-looking statements contained herein are made as at the date hereof and are based on the beliefs, estimates, expectations, and opinions of management on such date. Kontrol does not undertake any obligation to update publicly or revise any such forward-looking statements or any forward-looking statements contained in any other documents whether as a result of new information, future events or otherwise or to explain any material difference between subsequent actual events and such forward-looking information, except as required under applicable securities law. Readers are cautioned to consider these and other factors, uncertainties, and potential events carefully and not to put undue reliance on forward-looking information.
Posted by AGORACOM-JC
at 7:39 AM on Thursday, November 12th, 2020
Announced that its Cubeler Lending Hub commercial lending platform has facilitated the first transactions related to a program created by the Company and consumer electronics wholesale distributor Beijing Dianjing Company Ltd. (“BDC”) to bring financing solutions to BDC’s 60,000 online retail clients
Newly-created purchase order financing program allows BDC’s clients, who collectively sell about CAD$50B worth of consumer electronics per year, to have up to 90% of the price of the products they purchase financed by any bank or lending institution represented on the Lending Hub.
Purchase orders for iPhones totalling a combined 48M RMB (about CAD$9.5M) coming from four JD.com (www.jd.com) affiliated stores were the first orders approved for funding through the program
\Montreal, Quebec–(November 12, 2020) – Peak Positioning Technologies Inc. (CSE: PKK) (OTCQX: PKKFF) (“Peak” or the “Company”), an innovative Fintech service provider to the Chinese commercial lending sector, today announced that its Cubeler Lending Hub commercial lending platform has facilitated the first transactions related to a program created by the Company and consumer electronics wholesale distributor Beijing Dianjing Company Ltd. (“BDC”) to bring financing solutions to BDC’s 60,000 online retail clients.
The newly-created purchase order financing program allows BDC’s clients, who collectively sell about CAD$50B worth of consumer electronics per year, to have up to 90% of the price of the products they purchase financed by any bank or lending institution represented on the Lending Hub.
Purchase orders for iPhones totalling a combined 48M RMB (about CAD$9.5M) coming from four JD.com (www.jd.com) affiliated stores were the first orders approved for funding through the program. The platform collected a fee equivalent to 2% of the annualized interest rate charged by the lender to finance the orders. The financing program was expected to start in early December, but pressing demand from the stores led Peak and BDC to take special measures to allow for these first transactions to be processed while the program is still undergoing minor adjustments.
“Our market research showed that there would be strong demand from online retailers for Lending Hub’s services, but we weren’t expecting to have to start the program almost a full month ahead of schedule,” commented Peak Group China CEO, Mr. Liang Qiu. “Retailers continuously buy and sell inventory and thus have an ongoing need for credit, a need that wasn’t properly addressed until today. We created a program that uses AI and analytics to help retailers buy more products from wholesalers, and are working with some of the country’s largest wholesale distributors to expand it nationwide. I think we have a unique opportunity here to positively impact a large segment of China’s CAD$6.5 trillion annual retail market. This is yet another way in which we believe we can accelerate the proliferation of the Lending Hub to every part of the country.”
About Peak Positioning Technologies Inc.:
Peak Positioning Technologies Inc. is the parent company of a group of innovative financial technology (Fintech) subsidiaries operating in China’s commercial lending industry. Peak’s subsidiaries use technology, analytics and artificial intelligence to create an ecosystem of lenders, borrowers and other participants in China’s commercial lending space where lending operations are conducted rapidly, safely, efficiently and with the utmost transparency. For more information: http://peakfintechgroup.com/.
For more information, please contact:
CHF Capital Markets Cathy Hume, CEO 416-868-1079 ext.: 251 [email protected]
Peak Positioning Technologies Inc. Johnson Joseph, President and CEO 514-340-7775 ext.: 501 [email protected]
This news release may include certain forward-looking information, including statements relating to business and operating strategies, plans and prospects for revenue growth, using words including “anticipate”, “believe”, “could”, “expect”, “intend”, “may”, “plan”, “potential”, “project”, “seek”, “should”, “will”, “would” and similar expressions, which are intended to identify a number of these forward-looking statements. Forward-looking information reflects current views with respect to current events and is not a guarantee of future performance and is subject to risks, uncertainties and assumptions. The Company undertakes no obligation to publicly update or review any forward-looking information contained in this news release, except as may be required by applicable laws, rules and regulations. Readers are urged to consider these factors carefully in evaluating any forward-looking information.
